Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Susan O’Brien(The University of Texas MD Anderson Cancer Center), Richard R. Furman, Steven Coutré, Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Jan A. Burger(The University of Texas MD Anderson Cancer Center), Kristie A. Blum(The Ohio State University), Barbara Grant(University of Vermont), Donald Richards(Texas Oncology), Morton Coleman, William G. Wierda(The University of Texas MD Anderson Cancer Center), Jeffrey A. Jones(The Ohio State University), Weiqiang Zhao(The Ohio State University), Nyla A. Heerema(The Ohio State University), Amy J. Johnson(The Ohio State University), Raquel Izumi(Pharmacyclics (United States)), Ahmed Hamdy(Pharmacyclics (United States)), Betty Chang(Pharmacyclics (United States)), Thorsten Graef(Pharmacyclics (United States)), Fong Clow(Pharmacyclics (United States)), Joseph J. Buggy(Pharmacyclics (United States)), Danelle F. James(Pharmacyclics (United States)), John C. Byrd(The Ohio State University)
The Lancet Oncology
December 9, 2013
Cited by 465

Abstract


Related Papers

No related papers found

Powered by citation graph analysis